TY - JOUR
T1 - Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in surgically resected schwannomas
AU - Takahara, Kento
AU - Tamura, Ryota
AU - Kuranari, Yuki
AU - Karatsu, Kosuke
AU - Akiyama, Takenori
AU - Toda, Masahiro
N1 - Funding Information:
The authors thank Dr. Noboru Tsuda at the Department of Pathology, Keio University School of Medicine for technical assistance and Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
Copyright © 2023 Takahara, Tamura, Kuranari, Karatsu, Akiyama and Toda.
PY - 2023/2/10
Y1 - 2023/2/10
N2 - Objective: The goal of schwannoma resection is to control the tumor while preserving neurological function. Schwannomas have a variable postoperative growth pattern, therefore preoperative prediction of a schwannoma’s growth pattern is favorable. This study aimed to examine the relationship between preoperative neutrophil-to-lymphocyte ratio (NLR) and postoperative recurrence and retreatment in patients with schwannoma. Methods: We retrospectively examined 124 patients who underwent schwannoma resection in our institution. Associations between preoperative NLR, other patient and tumor characteristics, and tumor recurrence and retreatment were analyzed. Results: Median follow-up was 2569.5 days. Postoperative recurrence occurred in 37 patients. Recurrence that required retreatment occurred in 22. Treatment-free survival (TFS) was significantly shorter in patients with NLR ≥2.21 (P = 0.0010). Multivariate Cox proportional hazards regression showed that NLR and neurofibromatosis type 2 were independent predictors of retreatment (P = 0.0423 and 0.0043, respectively). TFS was significantly shorter in patients with NLR ≥2.21 in the following subgroups: sporadic schwannoma, primary schwannoma, schwannoma ≥30 mm in size, subtotal resection, vestibular schwannoma, and postoperative recurrence. Conclusions: Preoperative NLR ≥2.21 before surgery was significantly associated with retreatment after schwannoma resection. NLR may be a novel predictor of retreatment and assist surgeons in preoperative surgical decision making.
AB - Objective: The goal of schwannoma resection is to control the tumor while preserving neurological function. Schwannomas have a variable postoperative growth pattern, therefore preoperative prediction of a schwannoma’s growth pattern is favorable. This study aimed to examine the relationship between preoperative neutrophil-to-lymphocyte ratio (NLR) and postoperative recurrence and retreatment in patients with schwannoma. Methods: We retrospectively examined 124 patients who underwent schwannoma resection in our institution. Associations between preoperative NLR, other patient and tumor characteristics, and tumor recurrence and retreatment were analyzed. Results: Median follow-up was 2569.5 days. Postoperative recurrence occurred in 37 patients. Recurrence that required retreatment occurred in 22. Treatment-free survival (TFS) was significantly shorter in patients with NLR ≥2.21 (P = 0.0010). Multivariate Cox proportional hazards regression showed that NLR and neurofibromatosis type 2 were independent predictors of retreatment (P = 0.0423 and 0.0043, respectively). TFS was significantly shorter in patients with NLR ≥2.21 in the following subgroups: sporadic schwannoma, primary schwannoma, schwannoma ≥30 mm in size, subtotal resection, vestibular schwannoma, and postoperative recurrence. Conclusions: Preoperative NLR ≥2.21 before surgery was significantly associated with retreatment after schwannoma resection. NLR may be a novel predictor of retreatment and assist surgeons in preoperative surgical decision making.
KW - neurofibromatosis type 2
KW - neutrophil-to-lymphocyte ratio
KW - prognostic factor
KW - retreatment
KW - schwannoma
UR - http://www.scopus.com/inward/record.url?scp=85148593594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148593594&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1099384
DO - 10.3389/fonc.2023.1099384
M3 - Article
AN - SCOPUS:85148593594
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1099384
ER -